ANVS
Annovis Bio, Inc.Healthcare · $44M market cap
Verdict
We can't put a fair value on ANVS right now. The financial data we receive for it contains an obvious error (its cash-flow profit is more than 10× its reported profit for the same year). We'll value it once the data is corrected.
Business quality
0 of 5 clear the 10% bar. What are the Big Five?
Follow ANVS
Track it on your watchlist and see the full analysis. Free.
Create a free accountInsider activity
Since Nov 6, 2026: 1 open-market purchase worth $5.0M. Why purchases matter
Purchases
Questions about ANVS
Are insiders buying ANVS?
Since Nov 6, 2026: 1 open-market purchase worth $5.0M.
How can I check ANVS's value myself?
Use the free Sticker Price calculator, already filled with ANVS's numbers. Change the growth, P/E or required return and see what you'd pay. Open the calculator →
Similar stocks · Biotechnology
About Annovis Bio, Inc.
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases. This compound is also currently being evaluated in clinical studies for Alzheimer's disease in individuals with Down Syndrome, as well as for various other chronic neurodegenerative conditions. Beyond Buntanetap, Annovis Bio is developing ANVS405 to offer protection against traumatic brain injury and stroke. Additionally, ANVS301 is progressing through Phase I clinical trials, aiming to enhance cognitive capabilities in the later stages of Alzheimer's disease and broader dementia. The company was founded in 2008 and operates out of Berwyn, Pennsylvania.
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of Nov 6, 2026. How the Payback Price works